OncoHost, a technology company focused on precision medicine, announced on Monday that the Business Intelligence Group has named OncoHost as a winner in the 2026 BIG Innovation Awards in the Health category.
Additionally, OncoHost was selected as a Top 10 Innovator – Small Business, reflecting the company's leadership in developing clinically impactful technologies.
OncoHost was recognised for its PROphet platform, an AI-driven plasma-proteomics solution designed to help oncologists predict clinical benefit and therapy-related toxicity from a single pre-treatment blood test. Its first commercial offering, PROphetNSCLC, guides first-line immunotherapy decision-making in metastatic non-small cell lung cancer (NSCLC) by revealing host-response insights that extend beyond tumour-only biomarkers.
The BIG Innovation Awards are designed to honour organisations, products, and leaders transforming industries through applied innovation, intelligent platforms, and measurable real-world impact.
Beyfortus study shows sustained reduction in infant RSV hospitalisations across two seasons
AstraZeneca reports positive Phase III results for BREZTRI in uncontrolled asthma
Akeso's AK139 Phase II clinical trials approved in China
Median Technologies secures FDA clearance for AI lung cancer screening software
Insilico Medicine names new vice president, Clinical Development – Oncology
Cizzle Biotechnology secures Canadian patent for lung cancer biomarker test
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
United Therapeutics reports positive phase 1 data for bioengineered liver in acute liver failure
European Commission approves GSK's Arexvy for adults aged 18 and over